Compare Equinor ASA (EQNR) vs Summit Therapeutics Inc (SMMT) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Equinor ASA vs Summit Therapeutics Inc — how do they compare? Equinor ASA trades at $35.93 (market cap $82.75B), while Summit Therapeutics Inc trades at $13.77 (market cap $11.70B). The key difference: Equinor ASA is far larger — about 7.1× Summit Therapeutics Inc's market cap, and Equinor ASA pays a 4.24% dividend while Summit Therapeutics Inc pays none. Which is the better fit depends on your goals.
| EQNR | SMMT | |
|---|---|---|
Market Cap | $82.75B | $11.70B |
Sector | Energy | Health |
52-Week High | $42.40 | $29.32 |
52-Week Low | $22.41 | $13.05 |
Enterprise Value | $94.51B | $11.12B |
Dividend Yield | 4.24% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Equinor (EQNR) trades at $35.78, down 1.13% on the day, with a bullish technical signal from moving averages but overbought RSI readings. The company reported mixed recent earnings, beating expectations in Q1 2026 but missing in Q3 2025. Recent news highlights strategic investments in Norwegian Continental Shelf projects and a share buy-back program, while exiting non-core operations like Japan offshore wind.
EQNR presents a moderate investment case with a low P/E of 16.23 and strong cash flow, but faces risks from declining net income margins and volatile energy markets. Analyst sentiment is mixed with a 30% buy rating, suggesting cautious optimism amid execution and commodity price uncertainties.
Summit Therapeutics (SMMT) trades at $13.90, down 10.15% today, reflecting market reaction to mixed earnings and high volatility. The technical picture is bearish with weak moving averages, while fundamentals show significant losses with a net income of -$1.08B in 2025 and negative ROE/ROA. Recent news includes a $105M divestiture of ridinilazole to Biossil, sharpening focus on oncology, and upcoming Q2 2026 results on July 23, 2026.
Outlook hinges on clinical success of ivonescimab, with a bullish analyst consensus (66.7% buy ratings) and $15.57 price target suggesting 12% upside. Key risks include binary drug trial outcomes, cash burn from negative operating cash flow, and high short interest creating volatility. Investors face a high-risk, catalyst-driven opportunity dependent on pipeline execution.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Equinor ASA
Equinor is a Norway-based integrated oil and gas company. It has been publicly listed since 2001, but the government retains a 67% stake. Operating primarily on the Norwegian Continental Shelf, the firm produced 2.1 million barrels of oil equivalent per day in 2021 (52% oil) and ended the year with 5.4 billion barrels of proven reserves (49% oil). Operations also include offshore wind, solar, oil refineries and natural gas processing, marketing, and trading.
Read more on EQNR →About Summit Therapeutics Inc
Summit Therapeutics Inc. is a biopharmaceutical company focused on the development and commercialization of new medicines for the treatment of infectious diseases and other unmet medical needs. The company's lead product candidate is an antibiotic for the treatment of Clostridioides difficile infection (CDI), a serious infection of the colon. Summit Therapeutics is committed to bringing innovative therapies to market to address global health challenges and improve patient outcomes.
Read more on SMMT →
